Invitation to Presentations of Senzime's Second Quarter 2026 Report

Rhea-AI Summary

Senzime (OTCQX:SNZZF, STO:SEZI) will present its second quarter 2026 report on July 16, 2026. The report is scheduled for publication at 08:00 am CEST, followed by a CEO webcast at 09:00 am CEST and a live Q&A at 10:00 am CEST.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UPPSALA, SE / ACCESS Newswire / July 13, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) invites investors, analysts, and media to presentations of the second quarter report for 2026 on July 16. The report will be published at 08:00 am CEST the same day.

Philip Siberg, CEO of Senzime, will present the report through a webcast that can be seen from 09:00 am CEST on Senzime's website senzime.com/investors.

A Live Q&A, hosted by Gustaf Meyer, analyst at Redeye, will be aired at 10:00 am CEST via Redeyes platform. A recording of the Q&A will be published later the same day via Redeye's website redeye.se/company/senzime.

Questions for the Live Q&A interview can be emailed in advance, no later than July 16, 09:00 am CEST, to gustaf.meyer@redeye.se.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Invitation to presentations of Senzime's second quarter 2026 report

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

When will Senzime (SNZZF) release its Q2 2026 report?

Senzime will publish its Q2 2026 report on July 16, 2026 at 08:00 am CEST. According to Senzime, the release will be followed by a webcast presentation and a live Q&A session later the same morning.

How can investors watch Senzime’s Q2 2026 webcast presentation (SNZZF)?

Investors can watch Senzime’s Q2 2026 webcast from 09:00 am CEST on July 16, 2026 via the company’s website, senzime.com/investors. According to Senzime, CEO Philip Siberg will present the quarterly report during this online session.

How do I participate in Senzime’s live Q&A on July 16, 2026?

Senzime’s live Q&A will be aired at 10:00 am CEST on Redeye’s platform. According to Senzime, questions can be emailed in advance by 09:00 am CEST on July 16, 2026 to gustaf.meyer@redeye.se.

Where can I watch the recording of Senzime’s Q2 2026 Q&A session?

A recording of Senzime’s Q2 2026 live Q&A will be published later on July 16, 2026. According to Senzime, the replay will be available via Redeye’s website at redeye.se/company/senzime for investors and analysts.

Who will present Senzime’s Q2 2026 results and host the Q&A?

According to Senzime, CEO Philip Siberg will present the Q2 2026 report in a webcast. The live Q&A at 10:00 am CEST will be hosted by Gustaf Meyer, an analyst at Redeye, on Redeye’s platform.

How can I contact Senzime’s management about the Q2 2026 report (SNZZF)?

According to Senzime, investors can contact CEO Philip Siberg by phone at +46 (0) 707 90 67 34 or email philip.siberg@senzime.com, and CFO Slavoljub Grujicic at +46 (0) 76 306 60 11 or slavoljub.grujicic@senzime.com.